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http://www.biomedcentral.com/2050-6511/14/48RESEARCH ARTICLE Open AccessThe favorable kinetics and balance of
nebivolol-stimulated nitric oxide and peroxynitrite
release in human endothelial cells
R Preston Mason1,2, Robert F Jacob2, J Jose Corbalan3, Damian Szczesny3, Kinga Matysiak3 and Tadeusz Malinski3*Abstract
Background: Nebivolol is a third-generation beta-blocker used to treat hypertension. The vasodilation properties of
nebivolol have been attributed to nitric oxide (NO) release. However, the kinetics and mechanism of nebivolol-
stimulated bioavailable NO are not fully understood.
Methods: Using amperometric NO and peroxynitrite (ONOO-) nanosensors, β3-receptor (agonist: L-755,507;
antagonists: SR59230A and L-748,337), ATP efflux (the mechanosensitive ATP channel blocker, gadolinium) and
P2Y-receptor (agonists: ATP and 2-MeSATP; antagonist: suramin) modulators, superoxide dismutase and a NADPH
oxidase inhibitor (VAS2870), we evaluated the kinetics and balance of NO and ONOO- stimulated by nebivolol in human
umbilical vein endothelial cells (HUVECs). NO and ONOO- were measured with nanosensors (diameter ~ 300 nm) placed
5 ± 2 μm from the cell membrane and ATP levels were determined with a bioluminescent method. The kinetics and
balance of nebivolol-stimulated NO and ONOO- were compared with those of ATP, 2-MeSATP, and L-755,507.
Results: Nebivolol stimulates endothelial NO release through β3-receptor and ATP-dependent, P2Y-receptor activation
with relatively slow kinetics (75 ± 5 nM/s) as compared to the kinetics of ATP (194 ± 10 nM/s), L-755,507 (108 ± 6 nM/s),
and 2-MeSATP (105 ± 5 nM/s). The balance between cytoprotective NO and cytotoxic ONOO- was expressed as the
ratio of [NO]/[ONOO-] concentrations. This ratio for nebivolol was 1.80 ± 0.10 and significantly higher than that for ATP
(0.80 ± 0.08), L-755,507 (1.08 ± 0.08), and 2-MeSATP (1.09 ± 0.09). Nebivolol induced ATP release in a concentration-
dependent manner.
Conclusion: The two major pathways (ATP efflux/P2Y receptors and β3 receptors) and several steps of nebivolol-
induced NO and ONOO- stimulation are mainly responsible for the slow kinetics of NO release and low ONOO-. The
net effect of this slow kinetics of NO is reflected by a favorable high ratio of [NO]/[ONOO-] which may explain the
beneficial effects of nebivolol in the treatment of endothelial dysfunction, hypertension, heart failure, and angiogenesis.
Keywords: Nevibolol, Nitric oxide, Peroxynitrite, ATP, β3-adrenergic receptors, P2Y-purinergic receptorsBackground
Arterial endothelial cells modulate vascular tone through
release of nitric oxide (NO), a potent vasodilator that
regulates regional blood flow [1,2]. Beyond vasodilation,
NO has various vascular benefits that reduce the risk for
cardiovascular disease. NO inhibits smooth muscle cell
proliferation and migration, adhesion of leukocytes to
the vascular endothelium, and platelet aggregation [3].* Correspondence: malinski@ohio.edu
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reproduction in any medium, provided the orAn uncoupling of endothelial nitric oxide synthase
(eNOS) along with reduced endothelial-dependent NO
release and generation of peroxynitrite (ONOO-) has
been linked to atherogenesis and its clinical manifesta-
tions [4,5]. Agents that enhance NO bioavailability have
been shown to reduce cardiovascular events, as well as
central arterial blood pressure, in patients with hyper-
tension [4,5]. NO generation in the endothelium is ac-
companied by the production of ONOO-. Peroxynitrite,
a major component of nitroxidative stress, is cytotoxic
and can trigger a cascade of events leading to vasocon-
striction, dysfunction of the endothelium, and apoptosisLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ONOO- generated by the endothelium can significantly
affect the endothelial function, and as a result, lead to
the dysfunction of the cardiovascular system.
ATP, which widely regulates cell and tissue function
through autocrine or paracrine stimulation of purinergic
(P2Y) receptors, has also been shown to be an important
mediator of endothelial-dependent NO [7]. The vascular
effect of ATP was first characterized in aortic segments
from spontaneously hypertensive rats, as well as normo-
tensive Wistar-Kyoto rats, in which direct application of
ATP caused NO-mediated relaxation [8]. Similar effects
were observed in hepatic arterial tissue isolated from
New Zealand White rabbits and shown to be dependent
on endothelial P2Y receptors [9]. In renal tissue, isolated
from Wistar-Kyoto rats, ATP was further shown to in-
duce relaxation of the glomerular microvasculature by
activating P2Y receptors, followed by eNOS and guanylate
cyclase pathway activation [10].
Nebivolol is a third-generation, β1-adrenergic receptor
antagonist with vasodilatory properties that appear to be
independent of its β1-receptor interactions [11-13]. Its
mechanism of action is attributed to eNOS activation
since its vasodilatory effects can be reversed with spe-
cific eNOS inhibitors such as NG-monomethyl-L-arginine
(L-NMMA) and Nω-nitro-L-arginine methyl ester (L-
NAME) [14-16]. In a number of independent studies,
nebivolol-induced NO release has also been linked to β3-
receptor interactions as well as ATP-dependent, P2Y-
mediated eNOS activation [17-20]. Nebivolol has also
been reported to reverse eNOS uncoupling and interfere
with oxidative stress processes, by reducing NADPH oxi-
dase activity or by directly scavenging oxygen-derived free
radicals [13,20-23].
We conducted this study to evaluate simultaneously
the kinetics of nebivolol-stimulated NO and ONOO-
production and the role of ATP efflux along with P2Y-
and β3-receptor activation in human endothelial cells.
We hypothesized that the slow kinetics of NO release in
the endothelium, through integrated cellular mechanism
that include both the ATP autocrine and/or paracrine
pathway and these specific receptors, may be at least
partially responsible for favorable balance between bio-
available NO and cytotoxic ONOO-. The high level of
NO and low ONOO- generated by nebivolol may explain
its pleiotropic and therapeutic effects on the restoration
of endothelial function in the cardiovascular system.
Methods
Materials
Nebivolol HCl (in powder form) was provided by Forest
Research Institute (Commack, NY). The β3-agonist, L-
755,507, and β3-antagonists, SR59230A and L-748,337,
were purchased from Tocris Bioscience (Ellisville, MO).ATP, 2-MeSATP, and the non-selective P2Y receptor an-
tagonist, suramin, were purchased from Sigma-Aldrich
(St. Louis, MO). Gadolinium (Gd3+), a mechanosensitive,
ATP-release channel blocker, superoxide dismutase (PEG-
SOD) and the NADPH oxidase inhibitor, VAS2870, were
also purchased from Sigma-Aldrich.Cell culture
Primary human umbilical vein endothelial cells (HUVECs)
were purchased from Lonza Inc. (Walkersville, MD). Cells
were cultured in the recommended complete endothelial
cell growth medium and maintained at 37°C in a 95% air /
5% CO2 humidified incubator. As recommended by the
supplier, cells were supplied with fresh medium every
other day and propagated by an enzymatic (trypsin) pro-
cedure for a maximum of 16 population doublings. Our
studies were performed in accordance with the guidelines
established by the Ohio University Office of Institutional
Research Compliance. These guidelines conform with the
principles of the World Medical Association Declaration
of Helsinki.NO and ONOO- measurement
Endothelial NO and ONOO- release was measured using
amperometric nanosensors as previously described [21,24].
Briefly, each of the sensors was made by depositing a sens-
ing material on the tip of a carbon fiber (length 4-5 μm;
diameter 200-300 nm), i.e., a conductive film of polymeric
nickel(II)tetrakis(3-methoxy-4-hydroxyphenyl)porphyrin for
the NO sensor and a conductive film of polymeric manga-
nese(III)-[2]paracyclophenylporphyrin for the ONOO-
sensor. The fiber was sealed with a nonconductive epoxy
and connected to copper electrical wires with a conductive
silver epoxy. Confluent HUVECs were rinsed with endo-
thelial basal medium (EBM; Lonza Inc., Walkersville, MD)
and the tandem of nanosensors was gently lowered to
within 5 ± 2 μm from the surface of an endothelial cell
using a remote-controlled micromanipulator (Sensapex,
Finland). Amperometric measurements were performed
using a Gamry Reference 600™ dual potentiostat (Gamry
instruments, Warminster, PA). Basal NO and ONOO-
levels were measured by differential pulse voltammetry
(DPV) in separate experiments. The DPV current at the
peak potential characteristic for NO and ONOO- is dir-
ectly proportional to the local concentration of NO and
ONOO- in the immediate vicinity of the sensor. The
nanosensors were calibrated before measurements in cells
using a linear calibration curve (current versus concentra-
tion) constructed from standard NO or ONOO- solutions
ranging from 50 nM to 700 nM. The sensors response
and calibration was tested again after measurements in
cells, using the standard addition method. The detection
limit of the sensors was 10-9 M.
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of NO or ONOO-, were observed after the injection of
nebivolol and other agents used in this study, including
modulators of the ATP pathway and both agonists and
antagonists of the β3-receptor. To test their direct ef-
fects, the compounds were administered acutely by a
nanoinjector prior to measurements of NO and ONOO-
release from the cells. For combination studies, cells
were treated with various β3-receptor and ATP pathway
modulators, VAS2870 or PEG-SOD for 30 minutes prior
to treatment with nebivolol.
ATP measurement
Extracellular ATP was quantified using a luciferin-
luciferase assay kit (BioAssay Systems, Hayward, CA).
The ATP measurement was performed following the
supplier’s recommendations. Briefly, confluent HUVECs
were rinsed and incubated at 37°C in EBM medium for
5 minutes in the absence or presence of the various test
agents. Aliquots (100 μL) of each sample supernatant
were then transferred to a white opaque 96-well plate,
along with luciferin and luciferase, and then luminescence
was measured on a luminometer (BioTek, Winooski, VT).
The ATP concentration was obtained using a standard
calibration, prepared as recommended in the kit.
Calculations and statistical analysis
All data are presented as mean ± standard deviation
(SD) of the mean of n > 3. Statistical analysis of the mean
difference between multiple groups was performed using
one-way analysis of variance (ANOVA) with Student-
Newman-Keuls multiple comparisons post hoc analysis;
and between two groups, using Student’s t-test. The
alpha level for all the tests was 0.05. A P value <0.05 was
considered to be statistically significant. All statistical
analyses were performed using Origin (v 6.1 for Windows;
OriginLab, Northampton, MA) and GraphPad Prism
(v. 5.00 for Windows; GraphPad Software, San Diego, CA).
Results
Using nanonsensor technology, we measured in situ,
near-real time NO and ONOO- released from HUVECs
following the acute administration of nebivolol, L-755,
507, 2-MeSATP or ATP over a range of concentrations.
Representative amperograms (concentration/current vs.
time) collected from endothelial cells treated with
nebivolol, L-755,507, 2-MeSATP, and ATP are shown in
the Figure 1. A distinctive difference between the slope
and peak height of amperograms was observed for both
NO and ONOO- production. The slope of amperograms
was used to calculate the rate of NO and ONOO- gener-
ation by endothelial cells after stimulation with nebivolol,
L-755,507, 2-MeSATP, and ATP (Figure 2). The kinetics of
NO release was relatively slow for nebivolol, with a rate of75 ± 4 nM/s, and significantly faster for L-755,507 (108 ±
6 nM/s) and 2-MeSATP (105 ± 5 nM/s); and very fast for
ATP-stimulated NO release (194 ± 10 nM/s). The rates
for ONOO- followed this same pattern as NO – lowest
rate for nebivolol and the highest for ATP.
As shown in the Figure 3, the maximal NO concentra-
tion of 225 ± 15 nM was observed after stimulation with
nebivolol and was the highest among the four agents
tested. Surprisingly, ONOO- concentration was the low-
est after nebivolol stimulation (125 ± 10 nM) and the
highest after ATP stimulation (220 ± 13 nM). The max-
imal NO and ONOO- concentrations were between that
observed for nebivolol and ATP. We applied the ratio of
[NO] and [ONOO-] concentrations to depict the chem-
ical redox balance between these two molecules in the
cellular milieu. A decrease in [NO]/[ONOO-] ratio indi-
cates a decrease in the concentration of the cytoprotective
NO and/or an increase in the level of highly oxidative,
cytotoxic ONOO-. A ratio of [NO]/[ONOO-] below 1.0 is
an indicator that the cellular environment is dominated by
high oxidative/nitroxidative stress.
Nanosensors provide unique opportunities for the sim-
ultaneous measurement of NO and ONOO- concentration
in small volume (~10-15 L), at near real-time (10-5 s) in
close proximity to the cell membrane (~5 μm). The ratios
of [NO]/[ONOO-] are presented in the Figure 3B. There
is a highly significant difference in the [NO]/[ONOO-]
balance between nebivolol (1.80 ± 0.10) and ATP (0.80 ±
0.08). The ratio of [NO]/[ONOO-] for L-755,507 and 2-
MeSATP are similar, 1.08 ± 0.08 and 1.09 ± 0.09 respect-
ively. There is a 40-60% difference in the [NO]/[ONOO-]
balance between nebivolol and 3 other agents tested here.
A very low ratio of [NO]/[ONOO-] (lower than one)
was observed only after the stimulation of endothelial
cells by ATP (Figure 3B). We validated this model of
monitoring [NO]/[ONOO-] balance in endothelial cells
by changing the level of superoxide (O2
-), the precursor
of ONOO-. In the presence of membrane permeable PEG-
SOD (400 U/mL), a significant reduction in ONOO- con-
centration with concomitant increase in the NO level was
observed (Figure 4A). This effect was observed for both
nebivolol and ATP. A similar effect of the increase in NO
and proportional decrease in ONOO- was noticed in the
presence of NADPH oxidase inhibitor, VAS2870 (5 μM).
The Inhibition of the NADPH oxidase increases NO con-
centration by 20-30% after stimulation with nebivolol or
ATP. This indicates that about 20-30% of NO produced
by the endothelium is consumed by O2
- generated by
NADPH oxidase. The source of the remaining 70-80% of
O2
- in nebivolol- or ATP-stimulated endothelium is most
likely eNOS.
The decrease in O2
- had a significant influence on the
level of bioavailable NO and the concentration of
ONOO-, as reflected by a significant increase in [NO]/
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Figure 2 Rate of endothelial NO and ONOO- release. NO and
ONOO- release from HUVECs were stimulated with nebivolol, L-755,507,
2-MeSATP, and ATP (each at 1 μM). Values are mean ± SD (n = 5). One-
way ANOVA, Student-Newman-Keuls multiple comparison post-hoc
test: *P < 0.05 compared with either the rate of NO or ONOO- released
by cells stimulated with nebivolol.
Figure 1 Representative amperograms showing endothelial NO and ONOO- release stimulated with nebivolol, L-755,507, 2-MeSATP,
and ATP. NO (A) and ONOO- (B) release from HUVECs were stimulated with nebivolol, ATP, 2-MeSATP, or L-755,507 (each at 1 μM). The
amperograms of the 2-MeSATP partially overlaps that of L-755,507 and are omitted. NO and ONOO- release were measured with electrochemical
nanosensors positioned 5 ± 2 μm from the surface of a single cell. Arrows indicate compound administration.
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balance increased even further for nebivolol to 4.30 ±
0.21 in the presence of PEG-SOD. Also, in the presence
of PEG-SOD, a favorable shift in the [NO]/[ONOO-]
balance was observed for ATP.
Nebivolol increased endothelial NO release in a dose-
dependent manner (Figure 5A). The effect of nebivolol
on ATP concentration released from cells was significant
and correlated well with a dose-dependent increase in
NO production (Figure 5B). The ratio of [NO]/[ONOO-]
decreased with the increase of nebivolol concentration
(Figure 5C). This correlates well with a fast increase in
nebivolol-stimulated ATP component in the overall
stimulation process of NO release.
The relationship between NO bioavailability and ATP
production was further tested using modulators of the
ATP/purinergic pathway. Each of these agents signifi-
cantly attenuated the effects of nebivolol on endothelial
NO release (Figure 6A). At the specific concentrations
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Figure 3 Maximal endothelial NO and ONOO- concentrations,
and [NO]/[ONOO-] ratio stimulated with nebivolol, L-755,507,
2-MeSATP, and ATP. (A) Maximal NO and ONOO- concentration
release from HUVECs stimulated with nebivolol, L-755,507, 2-MeSATP,
and ATP (each at 1 μM). Values are mean ± SD (n = 5). One-way
ANOVA, Student-Newman-Keuls multiple comparison post-hoc test:
*P < 0.05 compared with either the maximal NO or ONOO- concentration
released by cells stimulated with nebivolol. (B) The [NO]/[ONOO-] ratio
calculated from the maximal concentration in A. Values are mean ± SD
(n = 5). One-way ANOVA, Student-Newman-Keuls multiple comparison
post-hoc test: *P < 0.05 compared with [NO]/[ONOO-] ratio calculated
for nebivolol.
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Figure 4 Maximal endothelial NO and ONOO- concentrations,
and [NO]/[ONOO-] ratio stimulated with nebivolol and ATP
following a PEG-SOD and VAS2870 incubation. (A) Maximal NO
and ONOO- concentrations stimulated with nebivolol and ATP (each
at 1 μM) following a 30-minute incubation of HUVECs with PEG-SOD
(400 U/mL) and VAS2870 (5 μM). Values are mean ± SD (n = 5).
Student’s t-test: *P < 0.05 compared with nebivolol. (B) The [NO]/
[ONOO-] ratio calculated from the maximal concentration in A.
Values are mean ± SD (n = 5). Student’s t-test: *P < 0.05 compared
with [NO]/[ONOO-] balance calculated for nebivolol.
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nebivolol-induced NO release by 50 and 60%, respect-
ively. These findings are consistent with the observation
that the effects of nebivolol on endothelial-dependent
NO release is casually associated with ATP production,
especially at higher concentrations of nebivolol. We also
measured the effects of nebivolol on endothelial NO
release in the presence of β3-receptor antagonists
SR59230A (1 μM) or L-748,337 (3 μM). Both of these
agents reduced the nebivolol-induced NO release by ap-
proximately 50% (Figure 6A). However, a combination of
suramin and SR59230A reduced nebivolol stimulated
NO by more than 90%.Discussion
The key finding from this study is that nebivolol-
stimulated NO release from human endothelial cells is
multipathway and slow. This slow process preserves
eNOS coupling and leads to a high production of bio-
available NO and low production of ONOO-. The slow
kinetics and dynamics of NO generation is a significant
factor in the maintaining of the highly favorable balance
between [NO] and [ONOO-] concentrations in the
endothelium. The favorable kinetics of NO release, com-
bined with O2
- scavenging by nebivolol, may help to ex-
plain the pleiotropic effect of nebivolol on the
cardiovascular system observed in clinical studies. The
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Figure 5 Maximal endothelial NO concentration, ATP release,
and [NO]/[ONOO-] ratio stimulated with nebivolol. Maximal NO
(A) and ATP (B) concentration release from HUVECs stimulated with
different concentrations of nebivolol, along with the [NO]/[ONOO-]
ratio (C). Values are mean ± SD (n = 5). One-way ANOVA, Student-
Newman-Keuls multiple comparison post-hoc test: *P < 0.05
compared with basal (in the absence of nebivolol) (A, B) and 0.1 μM
nebivolol (C).
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served for the other three agents presented in this study
(ATP, L-755,507, and 2-MeSATP). These three agents
produced comparable NO concentrations with nebivolol,
however, excessive and rapid NO production stimulated
by these agents eventually leads to uncoupling of eNOS
(rapid depletion of substrates and/or cofactors for NO
production). The uncoupled eNOS is an efficient gener-
ator of O2
- in one electron transfer reduction of oxygen.
Therefore, uncoupled eNOS can produce, sequentially,
both NO and O2
- . NO and O2
- generated in close proxim-
ity by eNOS can react rapidly in a diffusion controlled
reaction to produce ONOO-. The studies with VAS2870
also elucidated that the second major source of O2
- in
the endothelium during the stimulation of NO release
by nebivolol is NADPH oxidase. Our study shows that
after the stimulation of endothelial cells with nebivolol,
the contribution of NADPH oxidase to the pool of O2
- ,
and subsequently the pool of ONOO- is about 20-30%,
while about 70-80% of O2
- and ONOO- comes from
uncoupled eNOS. NADPH oxidase contribution to the
pool of O2
- and ONOO- after stimulation with ATP is
about 30-35% with eNOS contributing 65-70%. In
addition to the favorable kinetics of NO release,
nebivolol may also increase NO bioavailability through
non-receptor-mediated mechanisms, such as conveying
antioxidant benefits of the endothelium. Nebivolol has
been shown to scavenge O2
- independent of β3-receptor
blockade in animal and cell based models of cardiovas-
cular diseases [13,17,20,21]. These effects are attributed
to its specific interactions with plasma membrane and
its efficiency as a chain-breaking antioxidant [13,25].
Nebivolol has also been shown to interact with enzym-
atic sources of oxygen radicals such as NADPH oxidase
[21,22]. This correlates well with our data showing lower
generation of O2
-/ONOO- by NADPH oxidase than
eNOS after stimulation with nebivolol.
The scavenging properties of nebivolol cannot alone ex-
plain the low level of ONOO- and slow kinetics of
nebivolol stimulated NO production. The results of our
study suggest that nebivolol increases NO release in the
human endothelium through a complementary mechan-
ism involving β3-receptor, ATP autocrine and/or para-
crine, and P2Y-receptor activation. Two different
β3-receptor antagonists (SR59230A and L-748,337) were
discovered to significantly reduce nebivolol-induced NO
release in HUVECs. However, these β3-receptor antago-
nists reduced NO production only by about 50%. A block-
age with Gd3+ of mechanosensitive ATP channels of
HUVECs reduced NO production by 60%, indicating a
direct involvement of extracellular ATP in the stimulation
process. Finally, in the presence of both antagonists
of the P2Y-receptor, suramin, and β3-receptor antagonist,
SR59230A, NO concentration decreased by more than 90%.
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Figure 6 Major pathways involved in nebivolol-stimulated NO and ONOO- generation, and maximal endothelial NO concentration
stimulated with nebivolol alone or following an incubation with several modulators. (A) Maximal NO concentration release from HUVECs
stimulated with nebivolol (1 μM). Cells were also incubated with suramin (10 μM), Gd3+ (200 μM), SR59230A (1 μM), L-748,337 (3 μM) and suramin +
SR59230A for 30 minutes and NO release was stimulated with nebivolol (1 μM). Values are mean ± SD (n = 5). One-way ANOVA, Student-Newman-
Keuls multiple comparison post-hoc test: *P < 0.05 compared with nebivolol alone. (B) Nebivolol-stimulated generation of NO and ONOO- involves at
least two major pathways and several steps. (C) At low nebivolol concentration, K4 will be more determinant than at higher concentration. Values are
mean ± SD (n = 5). Student’s t-test: *P < 0.05 compared with K1 + K2 + K3.
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β3-receptors in eNOS activation and NO release in hu-
man endothelial cells stimulated by nebivolol. A role for
β3-receptors in nebivolol-induced NO release was previ-
ously demonstrated in human heart ventricular tissue
and coronary microarteries [19]. Nebivolol was shown to
activate cardiac β3-receptors in a manner similar to that
of the selective β3-receptor agonist, BRL 37344, both of
which resulted in a change in ventricular contraction at-
tributed to NO release. The negative inotropic effects ofnebivolol were modified by pretreatment with L-748,
337, but not with nadolol, a nonselective β2/β3-receptor
antagonist [19]. These specific receptor-mediated effects
of nebivolol on NO metabolism may contribute to favor-
able changes in vascular hemodynamic properties and
calcium regulation given the relative distribution of β1-
and β3-receptors in the failing heart. Clinical support for
such potential benefit was demonstrated in a random-
ized trial of elderly patients with documented heart fail-
ure [26]. Nebivolol was also shown in another study to
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for the regulation of coronary resistance and perfusion
reserve [18]. Endothelial-dependent vasodilation was not
reproduced with nebivolol in mice deficient for β3-receptors
[18]. Nebivolol also failed to induce neocapillary tube
formation in animals deficient in either β3-receptor or
eNOS expression [18]. Another recent study showed that
nebivolol increased levels of endothelial progenitor cells,
promoted angiogenesis, and reversed left ventricular dys-
function in mice with extensive myocardial infarction [20].
The vasodilation effects of nebivolol could only be
partially blocked with a specific β3-adrenergic receptor an-
tagonist [20]. The data presented in our work established
an important connection between the cardioprotective
effects of nebivolol and its β3-mediated, ATP-mediated ef-
fects on eNOS function.
The results of this study also suggest a role for the
ATP autocrine and/or paracrine pathway in the activa-
tion of eNOS. It was found that the mechanosensitive
ATP channel blocker, Gd3+, inhibited nebivolol-induced
NO release by 60%. Moreover, the rate of NO stimula-
tion with ATP is much faster than the stimulation with
nebivolol. Therefore, we concluded that a rate determin-
ing factor in the kinetics of nebivolol-stimulated NO
may be the ATP efflux from endothelial cells. The deliv-
ery of ATP from intracellular to extracellular space will
require a buildup of the gradient of concentration, passage
through mechanical channels and diffusion to receptors
on the membrane surface. These delivery processes, based
on efflux and diffusion, will be much slower than the
direct high gradient diffusion of ATP to membrane recep-
tors from an outer solution of ATP.
Extracellular ATP promotes vascular relaxation through
the activation of P2Y receptors and the subsequent stimu-
lation of eNOS and cytosolic guanylate cyclase [10].
Exogenous ATP has been shown to promote NO release
from Wister-Kyoto rat glomerular endothelial cells with
kinetic properties similar to those of nebivolol [17]. Inhib-
ition of ATP efflux with Gd3+, an inhibitor of stretch-
activated channels, also reduced the effects of nebivolol
[17]. We demonstrated that a pretreatment of cells with
Gd3+ decreased the ability of nebivolol-induced endothe-
lial NO release. This may suggest that nebivolol itself may
be linked to opening of mechanosensitive ATP channels.
It appears from this study that the kinetics of NO pro-
duction by eNOS is crucial in maintaining a favorable
balance between [NO]/[ONOO-] concentrations. A rapid
stimulation may produce high level of NO but also a
high level of ONOO-. Therefore, the rapid generation of
NO accompanied by high ONOO- cancels the beneficial
effect of NO and imposes a deleterious effect of ONOO- -
induced nitroxidative stress with severe side effect for the
endothelium. NO and ONOO- stimulation by cerivastatin
is a good example of this kind of “non-favorable kinetics”of NO release [27]. A potentially excellent pleiotropic ef-
fect of cerivastatin was compromised by the negative effect
of high ONOO- generated by this drug. This negative side
effect of cerivastatin on the cardiovascular system was the
forced withdrawal of this otherwise excellent drug from
the pharmaceutical market.
Limitations
HUVECs were used in this study as the sole source of
endothelial cells. Further studies will be required to con-
firm these findings using other sources of endothelial cells.
Conclusions
We propose that nebivolol-stimulated generation of NO
and ONOO- involves at least two major pathways and
several steps (Figure 6B). One of this pathways involves
a stimulation of intracellular ATP efflux through mech-
anical channels (K1), diffusion of extracellular ATP to
P2Y receptors (K2), and stimulation of P2Y receptors by
ATP (K3) followed by the release of NO and ONOO
-.
We propose that this pathway involving many steps is a
rate determining factor in NO and ONOO- production
after stimulation with nebivolol. The other pathway,
through β3 receptors (K4) is faster and the rate of NO
and ONOO- release comparable with that of K3. There-
fore, the yield of NO produced by each pathway will vary
with the concentration of nebivolol. At low nebivolol
concentration, K4 pathway will be more determinant
than at higher concentration (Figure 6C).
The results of this study provide additional insights
into the cellular basis for nebivolol-induced NO release
in human endothelial cells. The ability of nebivolol to
stimulate NO release appears to be independent of its
selective β1-blockade properties and dependent on
stimulation of β3-receptors and ATP-mediated stimula-
tion of P2Y-purinergic receptors. It seems to be also
linked to direct opening of mechanosensitive ATP chan-
nels. A multistep stimulation of NO release is relatively
slow and the production of NO does not significantly in-
fluence the supply of substrates or cofactors to eNOS,
maintaining its relative high degree of coupling. The
coupled eNOS can produce high NO concentration and
low ONOO- leading to a highly beneficial effect of
nebivolol in the treatment of dysfunctional endothelium
in cardiovascular diseases.
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